# Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

> **NCT01180790** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** ACH-0141625 (Sovaprevir)
- **DRUG:** ACH-0141625 (Sovaprevir)
- **DRUG:** ACH-0141625 (Sovaprevir)
- **DRUG:** Placebo
- **DRUG:** Pegylated Interferon alpha-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01180790
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-03
- **Final completion:** 2013-04
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01180790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01180790, "Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01180790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*